肠道菌群在肝细胞癌中的作用及治疗应用的研究进展

doi:10.11904/j.issn.1002-3070.2023.03.015

摘要/Abstract

摘要： 肝细胞癌(HCC)是全世界发病率和死亡率较高的肿瘤之一。由于肠道与肝脏有着密切而特殊的关系,肠道菌群可通过肠道与肝脏间的相互作用来影响慢性肝病,促进HCC的发生发展。本文着重介绍肠道菌群通过肠渗漏及MAMPs-Toll样受体、菌群失衡及其代谢产物、调节肿瘤微环境等方式促进HCC的发生发展。通过靶向肠道菌群,如抗生素杀灭有害菌群、拮抗剂抑制TLR、益生菌平衡失调菌群及FMT改善肠道菌群等为HCC的治疗提供新的策略。

关键词: 肝细胞癌, 肠道菌群, 慢性肝病, 肿瘤治疗

Abstract: Hepatocellular carcinoma(HCC)is one of the tumors with high morbidity and mortality in the world.Due to the close and special relationship between intestine and liver,gut microbiota can affect chronic liver disease and promote the occurrence and development of HCC through the interaction between intestine and liver.This article mainly introduces that gut microbiota promotes the occurrence and development of HCC through intestinal leakage and MAMPs Toll like receptors,imbalance of flora and its metabolites,and regulation of tumor microenvironment.Targeting gut microbiota,such as antibiotics to kill harmful flora,antagonists inhibiting TLR,probiotic imbalance of flora and FMT to improve gut microbiota,provides a new strategy for the treatment of HCC.

Key words: Hepatocellular carcinoma, Gut microbiota, Chronic liver disease, Tumor therapy

殷鼎威, 井杰. 肠道菌群在肝细胞癌中的作用及治疗应用的研究进展[J]. 实用肿瘤学杂志, 2023, 37(3): 281-286.

YIN Dingwei, JING Jie. Research progress on the role of Gut microbiota in hepatocellular carcinoma and its therapeutic application[J]. Journal of Practical Oncology, 2023, 37(3): 281-286.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2023.03.015

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2023/V37/I3/281

参考文献

1 Sung H,Ferlay J,Siegel RL,et al.Global Cancer Statistics 2020 GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Vitiello GA,Cohen DJ,Miller G.Harnessing the microbiome for pancreatic cancer immunotherapy[J].Trends Cancer,2019,5(11):670-676.
3 Garrett WS.Cancer and the microbiota[J].Science,2015,348(6230):80-86.
4 Whisner CM,Athena Aktipis C.The role of the microbiome in cancer initiation and progression:how microbes and cancer cells utilize excess energy and promote one another′s growth[J].Current Nutrition Reports,2019,8(1):42-51.
5 Aykut B,Pushalkar S,Chen R,et al.The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL[J].Nature,2019,574(7777):264-267.
6 Bonnet M,Buc E,Sauvanet P,et al.Colonization of the human gut by E.coli and colorectal cancer risk[J].Clin Cancer Res,2014,20(4):859-867.
7 Tripathi A,Debelius J,Brenner DA,et al.The gut-liver axis and the intersection with the microbiome[J].Nat Rev Gastroenterol Hepatol,2018,15(7):397-411.
8 Sender R,Fuchs S,Milo R.Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans[J].Cell,2016,164(3):337-340.
9 Flint HJ.Gut microbial metabolites in health and disease[J].Gut Microbes,2016,7(3):187-188.
10 Martinez KB,Leone V,Chang EB.Microbial metabolites in health and disease:navigating the unknown in search of function[J].J Biol Chem,2017,292(21):8553-8559.
11 Chu H,Duan Y,Yang L,et al.Small metabolites,possible big changes:a microbiota-centered view of non-alcoholic fatty liver disease[J].Gut,2019,68(2):359-370.
12 Wood S,Pithadia R,Rehman T,et al.Chronic alcohol exposure renders epithelial cells vulnerable to bacterial infection[J].PLoS One,2013,8(1):54646.
13 Chen P,Stärkel P,Turner JR,et al.Dysbiosis-induced intestinal inflammation activates tumor necrosis factor receptor I and mediates alcoholic liver disease in mice[J].Hepatology,2015,61(3):883-894.
14 Rohr MW,Narasimhulu CA,Rudeski-Rohr TA,et al.Negative effects of a high-fat diet on intestinal permeability:a review[J].Adv Nutr,2020,11(1):77-91.
15 Stenman LK,Holma R,Korpela R.High-fat-induced intestinal permeability dysfunction associated with altered fecal bile acids[J].World J Gastroenterol,2012,18(9):923-929.
16 阿比丹·拜合提亚尔郭津生.慢性肝病病因特异与非特异的肝细胞肝癌发生机制[J].泸州医学院学报,2021,44(6):593-600.
17 Lu H,Wu Z,Xu W,et al.Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection.Intestinal microbiota of HBV cirrhotic patients[J].Microb Ecol,2011,61(3):693-703.
18 Mutlu EA,Gillevet PM,Rangwala H,et al.Colonic microbiome is altered in alcoholism[J].Am J Physiol Gastrointest Liver Physiol,2012,302(9):966-978.
19 Said I,Ahad H,Said A.Gut microbiome in non-alcoholic fatty liver disease associated hepatocellular carcinoma:current knowledge and potential for therapeutics[J].World J Gastrointest Oncol,2022,14(5):947-958.
20 Albillos A,De Gottardi A,Rescigno M.The gut-liver axis in liver disease:pathophysiological basis for therapy[J].J Hepatol,2020,72(3):558-577.
21 Sandahl TD,Gronbaek H,Moller H J,et al.Hepatic macrophage activation and the LPS pathway in patients with alcoholic hepatitis:a prospective cohort study[J].Am J Gastroenterol,2014,109(11):1749-1756.
22 Petrasek J,Mandrekar P,Szabo GJGR, et al.Toll-like receptors in the pathogenesis of alcoholic liver disease[J].Gastroenterol Res Pract,2010,2010(12).
23 Hoyles L,Fernandez-Real JM,Federici M,et al.Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women[J].Nat Med,2018,24(7):1070-1080.
24 Abenavoli L,Scarpellini E,Colica C,et al.Gut microbiota and obesity:a role for probiotics[J].Nutrients,2019,11(11):2690.
25 Jiang C,Xie C,Li F,et al.Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease[J].J Clin Invest,2015,125(1):386.
26 Roderburg C,Luedde T.The role of the gut microbiome in the development and progression of liver cirrhosis and hepatocellular carcinoma[J].Gut Microbes,2014,5(4):441-445.
27 Yoshimoto S,Loo TM,Atarashi K,et al.Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome[J].Nature,2013,499(7456):97-101.
28 Yu LX,Yan HX,Liu Q,et al.Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents[J].Hepatology,2010,52(4):1322-1333.
29 Dapito DH,Mencin A,Gwak GY,et al.Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4[J].Cancer Cell,2012,21(4):504-516.
30 Schnabl B,Brenner DA.Interactions between the intestinal microbiome and liver diseases[J].Gastroenterology,2014,146(6):1513-1524.
31 Bajaj JS,Heuman DM,Hylemon PB,et al.Altered profile of human gut microbiome is associated with cirrhosis and its complications[J].J Hepatol,2014,60(5):940-947.
32 Lv LX,Fang DQ,Shi D,et al.Alterations and correlations of the gut microbiome,metabolism and immunity in patients with primary biliary cirrhosis[J].Environ Microbiol,2016,18(7):2272-2286.
33 De Minicis S,Rychlicki C,Agostinelli L,et al.Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice[J].Hepatology,2014,59(5):1738-1749.
34 Yamada S,Takashina Y,Watanabe M,et al.Bile acid metabolism regulated by the gut microbiota promotes non-alcoholic steatohepatitis-associated hepatocellular carcinoma in mice[J].Oncotarget,2018,9(11):9925-9939.
35 Lee WJ,Hase K.Gut microbiota-generated metabolites in animal health and disease[J].Nat Chem Biol,2014,10(6):416-424.
36 Ma C,Han M,Heinrich B,et al.Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells[J].Science,2018,eaan5931.
37 Li Q,Ma L,Shen S,et al.Intestinal dysbacteriosis-induced IL-25 promotes development of HCC via alternative activation of macrophages in tumor microenvironment[J].J Exp Clin Cancer Res,2019,38(1):303.
38 刘熙称,童曼曼,李凌巍,等.肠道菌群与肝细胞癌关系的研究进展[J].胃肠病学和肝病学杂志,2021,30(1):42-46.
39 Gangarapu V,Ince AT,Baysal B,et al.Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease[J].Eur J Gastroenterol Hepatol,2015,27(7):840-845.
40 Yu LX,Schwabe RF.The gut microbiome and liver cancer:mechanisms and clinical translation[J].Nat Rev Gastroenterol Hepatol,2017,14(9):527-539.
41 Hill C,Guarner F,Reid G,et al.Expert consensus document.The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic[J].Nat Rev Gastroenterol Hepatol,2014,11(8):506-514.
42 Li J,Sung CY,Lee N,et al.Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice[J].Proc Natl Acad Sci U S A,2016,113(9):1306-1315.
43 Zhang HL,Yu LX,Yang W,et al.Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats[J].J Hepatol,2012,57(4):803-812.
44 Elshaer AM,El-Kharashi OA,Hamam GG,et al.Involvement of TLR4/CXCL9/PREX-2 pathway in the development of hepatocellular carcinoma(HCC)and the promising role of early administration of lactobacillus plantarum in Wistar rats[J].Tissue Cell,2019,60:38-47.
45 Kang Y,Cai Y.Gut microbiota and hepatitis-B-virus-induced chronic liver disease:implications for faecal microbiota transplantation therapy[J].J Hosp Infect,2017,96(4):342-348.
46 Van Nood E,Vrieze A,Nieuwdorp M,et al.Duodenal infusion of donor feces for recurrent Clostridium difficile[J].N Engl J Med,2013,368(5):407-415.
47 Khoruts A,Rank KM,Newman KM,et al.Inflammatory bowel disease affects the outcome of fecal microbiota transplantation for recurrent clostridium difficile infection[J].Clin Gastroenterol Hepatol,2016,14(10):1433-1438.
48 Kang Y,Pan W,Cai Y.Gut microbiota and colorectal cancer:insights into pathogenesis for novel therapeutic strategies[J].Z Gastroenterol,2017,55(9):872-880.
49 Kang YB,Cai Y.Faecal microbiota transplantation enhances efficacy of immune checkpoint inhibitors therapy against cancer[J].World J Gastroenterol,2021,27(32):5362-5375.

[1]	崔永康, 于承平, 许浩志, 马新宇, 麻勇, 李林强. 营养风险指数在可切除肝细胞癌患者术后并发症及预后预测中的作用[J]. 实用肿瘤学杂志, 2023, 37(3): 243-251.
[2]	王嘉倍, 张运广, 刘连新. 免疫治疗联合分子靶向药物治疗中晚期肝细胞癌的临床疗效及安全性分析:一项单臂回顾性研究[J]. 实用肿瘤学杂志, 2022, 36(6): 489-494.
[3]	程思远, 韩子翰, 郭晓欢, 沈琳, 彭智. 肠道菌群与肿瘤免疫治疗疗效及不良反应关系的研究进展[J]. 实用肿瘤学杂志, 2022, 36(6): 520-525.
[4]	陈亚丽, 刘婷, 陈娟, 杜秋静. 癌症患者围术期肠道菌群与神经精神症状关系的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 468-471.
[5]	刘佳, 杨道坤, 王燕平, 陈宝鑫, 王新伟, 申娇. PD-1抑制剂治疗肝细胞癌疗效相关生物标志物的研究现状[J]. 实用肿瘤学杂志, 2022, 36(4): 374-380.
[6]	刘嘉铭, 崔逸峰, 陆朝阳. 槐耳清膏通过线粒体转录因子A调控Akt信号通路进而抑制肝细胞癌的增殖和转移[J]. 实用肿瘤学杂志, 2022, 36(3): 203-207.
[7]	刘雨, 俞星新, 耿志达, 陈政良, 惠鹏, 梁英健. 成纤维细胞在肝癌发生发展中的作用[J]. 实用肿瘤学杂志, 2022, 36(2): 167-172.
[8]	王宗文, 李小东, 朱乾坤, 曾世聪, 翟博. KIF14在肝细胞癌SMCC-7721获得性耐药机制中的研究[J]. 实用肿瘤学杂志, 2022, 36(1): 14-19.
[9]	刘菲, 隋红. 基于肿瘤免疫微环境的肝癌分子分型研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 557-561.
[10]	纪雷, 纪道林, 鲍冬冬, 谭刚. lncRNA在肝细胞癌索拉非尼耐药中的最新研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 562-567.
[11]	赵浩然, 李满, 张玉宝. 肝细胞癌相关RNA结合蛋白研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 576-579.
[12]	贺玲, 姚克铖. 糖基磷脂酰肌醇转酰胺酶与肝癌[J]. 实用肿瘤学杂志, 2021, 35(5): 458-461.
[13]	王恒敏, 赵琦, 吴华星. 粪便菌群移植在癌症治疗中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(5): 468-471.
[14]	秘嘉庆, 秦倩, 马惠涵, 马梅杰, 冯勤梅. TTK在肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(2): 188-192.
[15]	曲雁飞, 刘超, 王勃军, 方琳, 张艳桥. CSN6基因在肝细胞癌组织中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(4): 328-333.